Heart rate and cardiovascular protection

European Journal of Internal Medicine

Volumn 26, Issue 4, 2015, Pages 217-222

  Caetano, Joana ^a   Delgado Alves, José ^a,b  

^a HOSPITAL FERNANDO FONSECA   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Atherosclerosis; Autonomic dysfunction; Cardiovascular risk factors; Endothelial dysfunction; Heart rate variability; Resting heart rate

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; IVABRADINE; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; EPIDEMIOLOGICAL DATA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTING HEART RATE; REVIEW; ATHEROSCLEROSIS; CLINICAL TRIAL (TOPIC); HEART ARRHYTHMIA; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; ARRHYTHMIAS, CARDIAC; ATHEROSCLEROSIS; BENZAZEPINES; CARDIOVASCULAR AGENTS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HEART RATE; HUMANS; HYPERTENSION; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 84928829522     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2015.02.009     Document Type: Review

References (38)

1. H. Levine Rest heart rate and life expectancy J Am Coll Cardiol 30 1997 1104 1106
2. K. Fox, J.S. Borer, A.J. Camm, N. Danchin, R. Ferrari, J.L.L. Sendon, et al. Resting heart rate in cardiovascular disease J Am Coll Cardiol 50 2007 823 830
3. A. Hjalmarson Heart rate: an independent risk factor in cardiovascular disease Eur Heart J Suppl 9 Suppl. F 2007 F3 F7
4. S. Cook, M. Togni, M.C. Schaub, P. Wenaweser, and O.M. Hess High heart rate: a cardiovascular risk factor? Eur Heart J 27 2006 2387 2393
5. E. Kristal-Boneh, H. Silber, G. Harari, P. Froom, and J. Eur Heart The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS study) Eur Heart J 21 2000 116 124
6. A. Benetos, A. Rudnichi, F. Thomas, M. Safar, and L. Guize Influence of heart rate on mortality in a French population. role of age, gender and blood pressure Hypertension 33 1999 44 52
7. R.F. Gillum, D.M. Makuc, and J.J. Feldman Pulse rate, coronary heart disease and death: the NHANES I epidemiologic follow-up study Am Heart J 121 1991 172 177
8. M. Gillman, W.B. Kannel, A. Belanger, and R.B. D'Agostino Influence of heart rate on mortality among persons with hypertension: the Framingham Study Am Heart J 125 1993 1148 1154
9. A. Diaz, M.G. Bourassa, M.C. Guertin, and J.C. Tardif Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease Eur Heart J 26 2005 967 974
10. E. Disegni, U. Goldbourdt, H. Reicher-Reiss, E. Kaplinsky, M. Zion, V. Boyko, et al. The predictive value of admission heart rate on mortality in patients with acute myocardial infarction J Clin Epidemiol 48 1995 1197 1205
11. P. Lechat, J.S. Hulot, S. Escolano, A. Mallet, A. Leizorovicz, M. Werhlen-Grandjean, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial Circulation 103 2001 1428 1433
12. C.C. Lang, S. Gupta, P. Kalra, B. Keavney, I. Menown, C. Morley, et al. Elevated heart rate and cardiovascular outcomes in patients with coronary artery disease: clinical evidence and pathophysiological mechanisms Atherosclerosis 212 2010 1 8
13. H. Tsuji, M.G. Larson, F.J. Venditti, E.S. Manders, J.C. Evans, C.L. Feldman, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study Circulation 94 1999 2850 2855
14. H. Tsuji, F.J. Venditti, E.S. Manders, J.C. Evans, M.G. Larson, C.L. Feldman, et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study Circulation 90 1994 878 883
15. A. Haensel, P.J. Mills, R.A. Nelesen, M.G. Ziegler, and J.E. Dimsdale The relationship between heart rate variability and inflammatory markers in cardiovascular diseases Psychoneuroendocrinology 33 2008 1305 1312
16. Task Force of the European Society of Cardiology the North American Society of Pacing Heart rate variability. Standards of measurement, physiological interpretation, and clinical use Circulation 93 1996 1043 1065
17. J. Sztajzel Heart rate variability: a noninvasive electrocardiographic method to measure the autonomic nervous system Swiss Med Wkly 134 2004 514 522
18. F. Buccelletti, E. Gilardi, E. Scaini, L. Galiuto, R. Persiani, A. Biondi, et al. Heart rate variability and myocardial infarction: systematic literature review and meta-analysis Eur Rev Med Pharmacol Sci 13 2009 299 307
19. B. Wennerblom, L. Lurje, H. Tygesen, R. Vahisalo, and Hjalmarson Patients with uncomplicated coronary artery disease have reduced heart rate variability mainly affecting vagal tone Heart 83 2000 290 294
20. M.T. La Rovere, G.D. Pinna, S.H. Hohnloser, F.I. Marcus, A. Mortara, R. Nohara, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias Circulation 103 2001 2072 2077
21. J. Nolan, P.D. Batin, R. Andrews, S.J. Lindsay, P. Brooksby, M. Mullen, et al. Prospective study of heart rate variability and mortality in chronic heart failure Circulation 98 1998 1510 1516
22. F. Custodis, S.H. Schirmer, M. Baumhakel, G. Heusch, M. Bohm, and U. Laufs Vascular pathophysiology in response to increased heart rate J Am Cardiol 56 2010 1973 1983
23. T. Andrews, T. Fenton, N. Toyosaki, S.P. Glasser, P.M. Young, G. MacCallum, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity Circulation 88 1993 92 100
24. J.F. Aupetit, D. Frassati, B. Bui-Xuan, M. Freysz, G. Faucon, and Q. Tinour Efficacy of a β-adrenergic receptor antagonist, propranolol, in preventing ischaemic ventricular fibrillation: dependence on heart rate and ischaemia duration Cardiovasc Res 37 1998 646 655
25. M.H. Laughlin, S.C. Newcomer, and S.B. Bender Importance of hemodynamic forces as signals for exercise-induced changes in endothelial cell phenotype J Appl Physiol 104 2008 588 600
26. F. Custodis, M. Baumhakel, S.H. Schirmer, F. List, C. Gensch, M. Bohm, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice Circulation 117 2008 2377 2387
27. C. Giannattasio, A. Vincenti, M. Failla, A. Capra, A. Cirb, S. De Ceglia, et al. Effects of heart rate changes on arterial distensibility in humans Hypertension 42 2003 253 256
28. B. Hedbald, J. Wikstrand, L. Janzon, H. Wedel, and G. Berglund Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness. Main results from the β-blocker cholesterol-lowering asymptomatic plaque study (BCAPS) Circulation 103 2001 1721 1726
29. H.V. Huikuri, V. Jokinen, M. Syvanne, M.S. Nieminen, J. Airaksinen, M.J. Ikaheimo, et al. Heart rate variability and progression of coronary atherosclerosis Arterioscler Thromb Vasc Biol 19 1999 1979 1985
30. U.E. Heidland, and B.E. Strauser Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption Circulation 104 2001 1477 1482
31. J.C. Tardiff Heart rate as a treatable cardiovascular risk factor Br Med Bull 90 2009 71 84
32. M. Cucherat Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials Eur Heart J 28 2007 3012 3019
33. S. Bangalore, H. Makani, M. Radford, K. Thakur, B. Toklu, S.D. Katz, et al. Clinical outcomes with beta-blockers for myocardial infarction: a meta-analysis of randomized trials Am J Med 127 2014 939 953
34. K. Fox, I. Ford, G. Steg, M. Tendera, M. Robertson, and R. Ferrari Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial Eur Heart J 30 2009 2337 2345
35. M. Bohm, K. Swedberg, M. Komajda, J.S. Borer, I. Ford, A. Dubost-Brama, et al. Heart rate as risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial Lancet 376 2010 886 894
36. S. Banglore, S. Sawhney, and F.H. Messerli Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension J Am Coll Cardiol 52 2008 1482-1289
37. B. Williams, P.S. Lacy, S.M. Thom, K. Cruickshank, A. Stanton, D. Collier, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes Circulation 113 2006 1213 1225
38. C.H. Manisty, A. Zambanini, K.H. Parker, J.E. Davies, D.P. Francis, J. Mayet, et al. Differences in the magnitude of wave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure. An Anglo-Scandinavian Cardiac Outcome Trial Substudy Hypertension 54 2009 724 730